Stockscreener 앱 받기
4.33
5.46%
-0.25
시간 외 거래:
4.31
-0.02
-0.46%
전일 마감가:
$4.58
열려 있는:
$4.57
하루 거래량:
17.77M
Relative Volume:
0.42
시가총액:
$2.25B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-2.7935
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
-8.07%
1개월 성능:
-6.88%
6개월 성능:
-16.25%
1년 성능:
-37.97%
1일 변동 폭
$4.31
$4.6399
1주일 범위
$4.31
$5.0899
52주 변동 폭
$3.79
$12.36
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.33 | 2.38B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Nikko Asset Management Americas Inc. Sells 239,589 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025) - ts2.tech
Recursion Pharmaceuticals Insider Sale: Market Implications - timothysykes.com
Recursion rises on new data for asset for polyps - MSN
Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment (RXRX) - Seeking Alpha
Is Early REC-4881 Trial Success Reframing the AI-Drug Discovery Investment Case For Recursion (RXRX)? - simplywall.st
Jump Financial LLC Purchases 558,848 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Cautious Optimism for Recursion Pharmaceuticals: Promising TUPELO Study Results Lead to Hold Rating - TipRanks
Norges Bank Buys Shares of 3,169,938 Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Is There an Opportunity in Recursion Pharmaceuticals After Recent AI Drug Discovery Rally? - Yahoo Finance
Recursion Pharmaceuticals Reports Positive TUPELO Trial Results - TipRanks
Recursion Pharmaceuticals reports positive TUPELO trial results - MSN
Recursion Pharmaceuticals (RXRX): Revisiting Valuation After a Tentative Share Price Rebound - simplywall.st
Why Recursion Pharamaceuticals Topped the Market Today - MSN
Why Recursion Pharamaceuticals Topped the Market Today - The Motley Fool
Recursion Pharmaceuticals: Unraveling the Surge - timothysykes.com
Recursion Pharmaceuticals (RXRX) up 6.5% since last earnings report: Can it continue? - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap UpTime to Buy? - MarketBeat
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and TUPELO Trial Data - Quiver Quantitative
Promising Clinical Study Results and FDA Meeting Propel Buy Rating for Recursion Pharmaceuticals - TipRanks
Why Are Shares Of Recursion Pharmaceuticals Higher Today? - Benzinga
Recursion Pharmaceuticals Jumps as FAP Drug Candidate Shows Durable Efficacy - TradingPedia
Why Recursion Pharmaceuticals Shares Are in Focus Today - TipRanks
Recursion's Tupelo trial phase 1b/2 results show polyp burden reductions in FAP at 25 weeks - marketscreener.com
Recursion Pharmaceuticals stock surges after positive FAP trial data By Investing.com - Investing.com UK
Recursion’s FAP drug shows durable polyp reduction in phase 1b/2 trial - Investing.com
RXRX: REC-4881 achieved rapid, durable polyp burden reduction in FAP with a favorable safety profile - TradingView
Recursion Pharmaceuticals Announces Positive Phase 1b/2 Results for REC-4881 in FAP - TradingView — Track All Markets
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO - GlobeNewswire
Recursion Pharmaceuticals (RXRX) Is Up 8.0% After TUPELO REC-4881 Trial Data ReleaseWhat's Changed - Yahoo Finance
Jim Cramer on Recursion: "It Is so Low That It Comes in Under the Category of Speculative" - Finviz
Jim Cramer on Recursion: “It Is so Low That It Comes in Under the Category of Speculative” - Insider Monkey
Growth Value: Can Recursion Pharmaceuticals Inc stock maintain growth trajectoryQuarterly Portfolio Report & AI Enhanced Trading Alerts - moha.gov.vn
Recursion pharma CEO Gibson sells $185,200 in shares - Investing.com
Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 220,000 Shares of Stock - MarketBeat
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? - sharewise.com
Jim Cramer: This Health Care Stock Has Been 'Horrendous' - Benzinga
Recursion Pharmaceuticals Registers Resale of 7 Million Shares - MSN
Recursion Pharmaceuticals: Is It the Right Time to Buy? - StocksToTrade
Cramer's Lightning Round: Recursion Pharmaceuticals 'has been horrendous' - CNBC
Recursion Pharmaceuticals Insider Sold Shares Worth $961,400, According to a Recent SEC Filing - marketscreener.com
Recursion Pharmaceuticals: Is This Just The Beginning? - timothysykes.com
A Look At The Fair Value Of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - 富途牛牛
RECURSION PHARMACEUTICALS INC (RXRX.MX) Q1 FY2025 earnings call transcript - Yahoo Finance
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Clinical Data Readout - Quiver Quantitative
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade - InvestorPlace
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com
Capital Fund Management S.A. Has $3.65 Million Stock Holdings in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Can Recursion Pharmaceuticals Inc. stock continue upward trendQuarterly Profit Report & Advanced Swing Trade Entry Alerts - Newser
Is Recursion Pharmaceuticals Inc. stock attractive for hedge fundsMarket Trend Review & Verified Technical Signals - Newser
Quadrature Capital Ltd Takes Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
리커젼 파마 주식 (RXRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director |
Dec 02 '25 |
Sale |
4.37 |
220,000 |
961,400 |
6,869,863 |
1.08%
0.91%
자본화:
|
볼륨(24시간):